Trial Profile
Exploratory study of Xeloda+CDDP(XP)+Trastuzumab therapy for advanced gastric cancer with HER2 positive CTCs
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2017
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Trastuzumab (Primary)
- Indications Colorectal cancer; Gastric cancer
- Focus Biomarker; Therapeutic Use
- 14 Aug 2012 New trial record